Saturday 17 June 2017

Be a Part of IMA-PvPI Pharmacovigilance Initiative

Be a Part of IMA-PvPI Pharmacovigilance Initiative Report Adverse Reactions on +91-9717776514 Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem. WHO established its Programme for International Drug Monitoring in the year 1968 in response to the thalidomide disaster detected in 1961. The aims of pharmacovigilance are to enhance patient care and patient safety in relation to the use of medicines and to support public health programmes by providing reliable, balanced information for the effective assessment of the risk-benefit profile of medicines. IMA-PvPI Pharmacovigilance Initiative The Indian Pharmacopoeia Commission (IPC), National Coordination Centre (NCC) for Pharmacovigilance Programme of India (PvPI) and Indian Medical Association (IMA) have initiated the ways to promote reporting of Adverse Drug Reactions (ADRs) in the country. The Indian Pharmacopoeia Commission (IPC) is an autonomous institution of the Ministry of Health and Family Welfare, Govt. of India, which was created to set standards of medicines commonly used for treatment of diseases prevailing in our country. The IPC has been functioning as the National Coordination Centre for Pharmacovigilance Program of India (PvPI) since 15th April 2011 to monitor all adverse drug reactions taking place in the country. The mission of PvPI is to safeguard the health and welfare of the Indian population by monitoring drug safety and ensuring that the benefits of use of medicine outweigh the associated risks. IMA is the only representative, national voluntary organization of doctors of modern scientific system of medicine, which looks after the interest of doctors as well as the well–being of the community at large. IMA-PvPI initiative will work towards promoting patient safety in the country. We have agreed to cooperate and work together on the following: • PvPI–IMA patient safety monitoring cell to be started at the IMA Headquarters in New Delhi • Organizing Continuing Medical Educations (CMEs) • IMA to identify the nodal centers for education/advocacy and ADR monitoring and recommend to NCC–PvPI for recognition • Providing training to the nodal coordinators and medical officers • Development and upgradation of a mobile App for ADR monitoring • To propagate the concept of drug safety to patients via eMedinewS Under the IMA-PvPI initiative, Indian Medical Association (IMA) has become a nodal centre for reporting of ADRs under PvPI. IMA is compiling the data of ADRs related to drugs/vaccines/medical devices/blood products and herbal products. You can contact the IMA-PvPI ADR helpline and report any ADR/AE to Mr Hammad Ali on Mobile No. +91-9717776514 from Monday till Friday between 9am and 5:30pm. IMA Members should also report all ADRs - known or unknown, serious or non-serious - due to medicines, vaccines, blood products, herbal products and medical devices to PvPI Helpline No. 1800-180-3024 from Monday till Friday from 9am to 5:30pm. IMA Members should also report ADRs via PvPI ADR Android Mobile App (Download from Google Play Store). At IMA, we are committed to the safety of our patients. Be a Part of IMA-PvPI Pharmacovigilance Initiative. Report ADRs to safeguard your patient. Dr KK Aggarwal National President, IMA Dr RN Tandon Honorary Secretary General, IMA Hammad Ali Patient Safety Pharmacovigilance Associate IMA (HQ)-NCC PvPI Dr KK Aggarwal National President IMA & HCFI

No comments:

Post a Comment